Skip to content
Advertisement

This image provided by AstraZeneca shows the company's drug Imfinzi, known chemically as durvalumab. On Monday, May 1, 2017, the Food and Drug Administration approved Imfinzi, part of the new generation of immuno-oncology drugs, which help the immune system to fight off cancer. The FDA also approved a companion diagnostic test for identifying which patients are most likely to benefit from the drug. (AstraZeneca via AP)

This image provided by AstraZeneca shows the company's drug Imfinzi, known chemically as durvalumab. On Monday, May 1, 2017, the Food and Drug Administration approved Imfinzi, part of the new generation of immuno-oncology drugs, which help the immune system to fight off cancer. The FDA also approved a companion diagnostic test for identifying which patients are most likely to benefit from the drug. (AstraZeneca via AP)

Featured Photo Galleries